Bloomberg Law
Pharmaceutical & Life Sciences News

Latest Stories

Astellas Loses Bid to Block Myrbetriq Copies During Patent Suit

A federal judge rejected Astellas Pharma Inc.’s requests to block Lupin’s and Zydus’ copies of the overactive-bladder treatment Myrbetriq during a patent-infringement suit, finding an injunction in a related appeal doesn’t change the court’s assessment that Astellas is unlikely to overcome invalidity arguments.